American Genomics

American Genomics is a private U.S. ophthalmology-focused biotech company developing and commercializing topical ocular anesthetics. Its lead and apparently sole disclosed product is Cyklx, an articaine ophthalmic solution 8% for ocular surface anesthesia prior to ocular procedures and intraocular injections in adults and pediatric patients. The company sponsored multiple completed Phase 3 studies of AG-920, the development code for Cyklx, and received FDA approval for the product in 2025. Publicly available materials indicate the company is led by ophthalmologist-entrepreneur Martin Uram and operates from New Jersey and Florida addresses. Based on available disclosures, American Genomics appears to be a single-product specialty pharmaceutical company rather than a broad genomics platform business.